Developing Therapies for Congenital Muscular Dystrophies | Wednesday May 3, 2023 | 3:00 pm–4:00 pm CEST / 9:00 am–10:00 am EDT
On-demand webinar is available - Follow this link
Developing Therapies for Congenital Muscular Dystrophies: Gene Editing of Dominant Mutations in Collagen VI Genes Restores the Extracellular Matrix in Patient Cells
Despite being the second most common form of congenital muscular dystrophies, there are currently no effective treatments available for collagen VI-related dystrophies (COL6-RDs), a fact that Dr. Cecilia Jiménez-Mallebrera and her research team hope to change using CRISPR technology.
Jiménez-Mallebrera has been studying neuromuscular diseases for almost her entire career, specialising in ultra-rare congenital muscular dystrophies in paediatric patients. Currently the director of the Laboratory of Translational Research in Children’s Neuromuscular Diseases at IRSJD, her work spans the pathophysiology and diagnosis of these conditions through to clinical trials.
Her recent paper, published in the International Journal of Molecular Sciences, demonstrated the use of CRISPR-Cas9 gene editing to alleviate the pathogenic effects of a dominant negative mutation in the COL6A1 gene.
What will you learn from this webinar:
Congenital muscular dystrophies: the extracellular matrix in muscle diseases.
In vitro gene editing of human fibroblasts.
The relevance of using a range of precise and sensitive techniques to evaluate the efficiency of gene editing.
- 15.00 Welcome and introduction by CRISPR Medicine News
- 15.05 Dr. Cecilia Jimenez-Mallebrera PhD |Developing Therapies for Congenital Muscular Dystrophies
- 15.45 Q & A with Cecilia Jimenez-Mallebrera PhD
- 16.00 Close by CRISPR Medicine News
Speaker | Title:
Dr. Cecilia Jimenez-Mallebrera PhD, Institut de Recerca Sant Joan de Déu, Barcelona, Spain | Developing Therapies for Congenital Muscular Dystrophies
Dr. Cecilia Jimenez-Mallebrera PhD, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Dr. Cecilia Jimenez-Mallebrera received her PhD in Genetics from the University of London in 2001, and trained in Neuromuscular Diseases at the Dubowitz Neuromuscular Centre under the supervision of Francesco Muntoni and Caroline Sewry. Her research focused on the then emerging congenital muscular dystrophies related to the extracellular matrix, in particular the alpha-dystroglycan glycosylation defects and collagen VI-related dystrophies.
In 2010, she moved to Barcelona Children´s Hospital with a Spanish Government starting grant where she established a translational and multidisciplinary research group which she has lead since then. The Neuromuscular Group is part of the Institut de Recerca Sant Joan de Déu which specialises in research in rare paediatric diseases. The laboratory is an international referral centre for the diagnosis of collagen VI-related disorders, which has driven the development of novel and precise tools including advanced microscopy and machine learning for the study of collagen VI. The group was the first to describe the transcriptome of fibroblasts and skeletal muscle from patients with collagen VI-related dystrophies. which helped towards the understanding of the disease mechanisms. In the last 5 years, they have been investigating mutation-correcting strategies for these conditions with antisense oligonucleotides and CRISPR-Cas9.
Dr. Jimenez-Mallebrera participates in several initiatives to promote the development of advanced therapies for neuromuscular diseases including the COST Action on Delivery of Antisense RNA Therapeutics (DARTER) and the Spanish CIBERER working group on Gene Therapy and Genome Editing. She combines her research with a faculty position in the Department of Genetics at the University of Barcelona, and she is the current president of the Scientific Committee of the Institut de Recerca Sant Joan de Déu. Her work has so far resulted in more than 90 publications in peer-reviewed journals and 1 patent, and her research is supported by various public national and international agencies (mainly the Instituto de Salud Carlos III) and private foundations such as Fundación Noelia for Collagen VI-Related Dystrophies.
Read our CMN interview with Dr. Cecilia Jimenez-Mallebrera here.
CMN Webinars - Your Gateway to CRISPR Medicine
If you have any questions or request for webinars, please contact us at: firstname.lastname@example.org
Future CMN Webinars will be listed here.
Always stay updated - Sign up to weekly newsletter.
CMN Articles - Muscular Dystrophies